Affiliation:
1. Division of Postgraduate Studies and Research, Tecnológico Nacional de México, Instituto Tecnológico de Oaxaca , Oaxaca City , Oaxaca , México
2. Faculty of Medicine and Surgery, Facultad de Medicina y Cirugía, Universidad Autónoma “Benito Juárez” de Oaxaca , Oaxaca City , Oaxaca , México
Abstract
Abstract
Dyslipidemias are a group of diseases, which are characterized by abnormal blood concentrations of cholesterol, triglycerides and/or low-density lipoprotein-cholesterol (LDL-c). Dyslipidemia is a determinant condition for the progress of an atherosclerotic plaque formation. The resulting atherogenicity is due to at least two mechanisms: first, to the accumulation in the plasma of lipid particles that have the capacity to alter the function of the endothelium and deposit at the atheromatous plaque, and second, at an insufficient concentration of multifactorial type of high density lipoprotein-cholesterol (HDL-c), whose function is to protect against the development of atherosclerosis. Its highest prevalence is encountered among individuals with diabetes, hypertension or overweight. Hyperlipidemia is one of the main predisposing factors for the development of cardiovascular disease. Hyperlipidemia can be the result of a genetic condition, the secondary expression of a primary process or the consequence of exogenous factors (food, cultural, socio-economic, etc.), all of which lead to the elevation of plasma lipid levels. The objective of this study was to carry out an analysis of the genes involved in the development of dyslipidemias that lead to cardiovascular disease with special emphasis on the proprotein convertase subtilin/kexin type 9 (PCSK9) gene. The PCSK9 gene participates in the development of primary dyslipidemias, mainly familial hypercholesterolemia, currently the pharmacological treatment of choice to reduce LDL-c are statins, however, it has been observed that these have been insufficient to eliminate cardiovascular risk, especially in subjects with primary forms of hypercholesterolemia related to genetic mutations, or statin intolerance.
Subject
Genetics (clinical),Genetics
Reference88 articles.
1. Díaz-Aragón A, Fernández-Barros CL, Enciso-Muñoz JM, Ceballos-Reyes G, Gutiérrez-Salmeán G, León Hernández FJ, et al.e. Posicionamiento en torno al diag-nóstico y tratamiento de las dislipidemias. Rev Mex Cardiol. 2018; 29(3): 148-168.
2. World Health Organization. Cardiovascular diseases (CVDs). [http://www.who.int/news-room/fact-sheets/detail/cardiovasculard-diseases-(cvds); accessed June 13 2020].
3. Barquera S, Pedroza-Tobías A, Medina C, Hernández-Barrera L, Bibbins-Domingo K, Lozano R, et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res. 2015; 46(5): 328-338.
4. Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality from ischemic heart disease. Circ Cardiovasc Qual Outcomes. 2019; 12(6): e005375.
5. Martinez-Sanchez C, Borrayo G, Carrillo J, Juarez U, Quintanilla J, Jerjes-Sanchez C. Clinical management and hospital outcomes of acute coronary syndrome patients in Mexico: The Third National Registry of Acute Coronary Syndromes (RENASICA III). Arch Cardiol México. 2016; 86(3): 221-232.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献